Research programme- anti-Alzheimer's therapeutics transdermal- ALZYN

Drug Profile

Research programme- anti-Alzheimer's therapeutics transdermal- ALZYN

Latest Information Update: 21 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Florida State University
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 20 Sep 2016 ALZYN and Transdermal Delivery Solutions enter into an agreement for licensing of a transdermal HypoSpray®-delivered solution
  • 20 Sep 2016 ALZYN in-licenses science from Florida State Research Foundation for development of transdermally administered therapeutics for Alzheimer's disease
  • 20 Sep 2016 Preclinical trials in Alzheimer's disease in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top